Short Interest in Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Increases By 669.3%

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) saw a large increase in short interest in the month of January. As of January 30th, there was short interest totaling 52,373 shares, an increase of 669.3% from the January 15th total of 6,808 shares. Approximately 1.7% of the company’s stock are sold short. Based on an average daily trading volume, of 86,857 shares, the short-interest ratio is presently 0.6 days. Based on an average daily trading volume, of 86,857 shares, the short-interest ratio is presently 0.6 days. Approximately 1.7% of the company’s stock are sold short.

Institutional Trading of Scinai Immunotherapeutics

An institutional investor recently raised its position in Scinai Immunotherapeutics stock. Citadel Advisors LLC lifted its stake in Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,630 shares of the company’s stock after acquiring an additional 17,031 shares during the period. Citadel Advisors LLC owned approximately 0.90% of Scinai Immunotherapeutics worth $36,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 58.41% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a research report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Scinai Immunotherapeutics Stock Down 2.5%

Scinai Immunotherapeutics stock traded down $0.02 during mid-day trading on Thursday, reaching $0.78. 4,546 shares of the company’s stock were exchanged, compared to its average volume of 45,930. The firm has a market capitalization of $2.49 million, a PE ratio of -0.08 and a beta of 1.88. The business’s fifty day simple moving average is $0.89 and its 200 day simple moving average is $1.21. Scinai Immunotherapeutics has a one year low of $0.61 and a one year high of $6.18.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.